Solid tumours - NTRK gene fusion positive

The PBS subsidises larotrectinib for patients with solid tumours that are confirmed to be neurotrophic tropomyosin receptor kinase (NTRK) gene fusion positive.

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with larotrectinib under the National Health Act 1953, section 85 for patients with solid tumours that are confirmed to be NTRK gene fusion positive.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing larotrectinib.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised larotrectinib to treat solid tumours that are NTRK gene fusion positive can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised larotrectinib to treat solid tumours that are NTRK gene fusion positive can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 July 2022